Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NCI

PYRIMIDINE AND PURINE 1,2 - BUDADIENE - 4 - OLS AS ANTI-RETROVIRAL AGENTS

  • Read more about PYRIMIDINE AND PURINE 1,2 - BUDADIENE - 4 - OLS AS ANTI-RETROVIRAL AGENTS
European Patent
89901635.6
Filed on 1988-12-30

PYRIMIDINE AND PURINE 1,2 - BUDADIENE - 4 - OLS AS ANTI-RETROVIRAL AGENTS

  • Read more about PYRIMIDINE AND PURINE 1,2 - BUDADIENE - 4 - OLS AS ANTI-RETROVIRAL AGENTS
China
88109289.4
Filed on 1988-12-30

PYRIMIDINE AND PURINE 1,2 - BUDADIENE - 4 - OLS AS ANTI-RETROVIRAL AGENTS

  • Read more about PYRIMIDINE AND PURINE 1,2 - BUDADIENE - 4 - OLS AS ANTI-RETROVIRAL AGENTS
Canada
587386
Filed on 1988-12-30

PYRIMIDINE AND PURINE 1,2 - BUDADIENE - 4 - OLS AS ANTI-RETROVIRAL AGENTS

  • Read more about PYRIMIDINE AND PURINE 1,2 - BUDADIENE - 4 - OLS AS ANTI-RETROVIRAL AGENTS
Australia
29477/89
Filed on 1988-12-30

Immortalized Human Bronchial Epithelial Mesothelial Cell Lines (ATCC/CRL 9441)

  • Read more about Immortalized Human Bronchial Epithelial Mesothelial Cell Lines (ATCC/CRL 9441)
Canada
581739
Filed on 1988-10-29

NEW ANTI-RECEPTOR PEPTIDES AND THERAPUTIC AGENTS

  • Read more about NEW ANTI-RECEPTOR PEPTIDES AND THERAPUTIC AGENTS
Australia
26230/88
Filed on 1988-10-14

HUMAN CELL LINES OF EPITHELIAL LUNG ADENOCARCINOMA ORIGIN, HUMAN PROTEINS AND METHODS

  • Read more about HUMAN CELL LINES OF EPITHELIAL LUNG ADENOCARCINOMA ORIGIN, HUMAN PROTEINS AND METHODS
Taiwan
78102874
Filed on 1988-09-27

HUMAN CELL LINES OF EPITHELIAL LUNG ADENOCARCINOMA ORIGIN, HUMAN PROTEINS AND METHODS

  • Read more about HUMAN CELL LINES OF EPITHELIAL LUNG ADENOCARCINOMA ORIGIN, HUMAN PROTEINS AND METHODS
Norway
892133
Filed on 1988-09-27

HUMAN CELL LINES OF EPITHELIAL LUNG ADENOCARCINOMA ORIGIN, HUMAN PROTEINS AND METHODS

  • Read more about HUMAN CELL LINES OF EPITHELIAL LUNG ADENOCARCINOMA ORIGIN, HUMAN PROTEINS AND METHODS
South Korea
700929/89
Filed on 1988-09-27

SECOND GENERATION MONOCLONAL ANTIBODIES HAVING BINDING SPECIFICITY TO TAG-72 AND HUMAN CARCINOMAS AND .......

  • Read more about SECOND GENERATION MONOCLONAL ANTIBODIES HAVING BINDING SPECIFICITY TO TAG-72 AND HUMAN CARCINOMAS AND .......
Canada
571894
Filed on 1988-07-13

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 1374
  • Page 1375
  • Page 1376
  • Page 1377
  • Page 1378
  • Page 1379
  • Page 1380
  • Page 1381
  • Page 1382
  • …
  • Next page ››
  • Last page Last »
Subscribe to NCI
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health